Bone Biologics Corporation, a company specializing in orthobiologic products for spine fusion, has filed a patent application with the United States Patent and Trademark Office for its new NELL-1 protein technology. This development is aimed at enhancing bone regeneration treatments. The patent focuses on the compositions and uses of the rhNELL-1 polypeptide for treating bone conditions. If approved, this will bolster Bone Biologics' intellectual property assets and aid in advancing their clinical development program. The announcement was made by Jeffrey Frelick, the company's CEO, marking a significant step in their mission to improve spine fusion treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.